35TH ANNUAL CFS: INNOVATIVE CANCER THERAPY FOR TOMORROW®
New York Marriott Marquis Hotel *New York City, USA Visit the Venue to read more
Advances in all aspects of cancer care—including diagnostic, therapeutic, and supportive strategies—form the foundation for recent changes in the management of solid and hematologic malignancies. For many tumor types, integration into practice of novel testing approaches, systemic therapies, molecular targeted therapies, immunotherapies, and multimodal strategies, continue to improve patient outcomes in multiple lines of care. Each year, the CFS®, brings together more than 2,000 oncologists, hematologists, radiation oncologists, immunologists, pharmacists, oncology nurses, nurse practitioners, physician assistants, and case managers, with the aim of promoting the delivery of state-of-the-art cancer care for the most challenging clinical scenarios. At the 34th Annual CFS®, our internationally renowned faculty will provide expert insights on the latest developments in cancer therapeutics. This exciting 3-day program will offer oncology practitioners an unparalleled opportunity to learn how innovative approaches fit into evolving treatment paradigms to optimize care and outcomes for their patients with cancer.
This educational activity is directed toward oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend.
2017 Hot Topics
Immunotherapies and Their Latest Applications in Cancer, Including Combinations
Harnessing the Latest Technologies, Biomarkers, and Tests to Optimize Clinical Decision Making
Microsatellite Instability‒Guided Care Across Multiple Tumor Types
How to Maximize Outcomes in Multiple Myeloma
Factoring MRD Into Treatment Plans for Patients With Hematologic Malignancies
Tackling Clinical Challenges in the Management of Myeloproliferative Neoplasms
Practice-Changing Paradigms in Acute Leukemias
Providing State-of-the-Art Care for Older Patients With Hematologic Malignancies
Coming Soon to Your Clinic: Evolving Strategies for Hepatocellular Carcinoma, Pancreatic Cancer, and Gastric Cancer
Options and Considerations for Metastatic Colorectal Cancer in the Frontline and Beyond Progression
Progress in Soft-Tissue Sarcoma and Non‒Soft-Tissue Sarcoma
Ovarian Cancer: PARP Inhibition, Maintenance Strategies, Immunotherapy, Angiogenesis Targeting, and Clinical Trial Designs
Novel Therapeutic Approaches in Breast Cancer Treatment: Immunotherapy and Combinations
Treatment Planning for Early, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Considerations
Individualized Care for Patients With Advanced Triple-Negative Breast Cancer
Precision Care for Patients With Non-Small Cell and Small Cell Lung Cancer
Bladder Cancer: More Options, More Clinical Considerations
New Horizons in Prostate Cancer: Expert Sequencing, Targeting DNA Repair Deficiency, and Immunotherapy
Updates in Glioblastoma: Technologies, Targeted Therapy, and Immunotherapy
Optimizing Your Patients’ Quality of Life: Focus on CINV, Sexuality, and Palliation
Advances in Melanoma and Nonmelanoma Carcinomas
Cancer-Associated Cardiomyopathy: Web-Based Diagnostic and Management Technologies
Moon Shots Program™ Update
Ajai Chari, MD
Medicine, Hematology and Medical Oncology
The Mount Sinai Hospital
New York, NY
Maura N. Dickler, MD
Interim Chief, Breast Medicine Service
Section Head, Endocrine Therapy Clinical Research Program
Associate Member, Memorial Sloan Kettering Cancer Center
Division of Solid Tumor Oncology
Department of Medicine
Associate Professor of Medicine, Weill Cornell Medical College
New York, NY
Alexander Drilon, MD
Clinical Director, Early Drug Development Service
Assistant Attending Physician, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Cathy Eng, MD, FACP
Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Director, Department of Gastrointestinal Medical Oncology, Network Clinical Research
Associate Medical Director, Colorectal Center, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Jason Luke, MD, FACP
Assistant Professor of Medicine
The University of Chicago Medicine
Edward Ambinder, MD
Medicine, Hematology and Medical Oncology Clinical
Professor, Oncological Sciences
Mount Sinai Hospital
New York, NY
Franco Muggia, MD
Professor, Department of Medicine
NYU Langone Medical Center
New York, NY
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
New York Marriott Marquis
New York, NY 10036
A limited block of rooms has been set aside at the New York Marriott Marquis at a run-of-house rate of $397 (single/double) plus applicable state and local taxes. Rates and rooms are subject to availability at the time of the reservation.
To make a reservation, call (800) 843-4898. The deadline for making your hotel reservations is October 16, 2017. After that date, or in the event that the room block becomes full prior to the deadline, rooms are subject to availability, and the room rates may increase. When booking, please mention the CFS™ to receive the discounted group rate. All reservations must be accompanied by a first night room deposit or guaranteed with a major credit card.
All reservations must be accompanied by a first night room deposit or guaranteed with a major credit card. The hotel will not hold any reservations unless secured by one of the above methods.
Physicians’ Education Resource® (PER®) recommends that you make your airline reservations early to get the best seat options and lowest airfare available. The gateways to the NYC area are LaGuardia Airport (LGA, 9.5 miles) and John F. Kennedy International Airport (JFK, 18.5 miles) in NY, and Newark Liberty International Airport located in NJ (EWR, 16.5 miles).
You are invited to make your travel arrangements through PER’s travel partner, Singer Travel, at (610) 378-1610 between 9:00 am and 5:30 pm Eastern Standard Time. Please ask for Jill Schuler.
All poster abstract submissions must be made electronically through the PER® online abstract submission system.
The abstract should be a short description of your work and should contain all the elements necessary to define your goals and results to the reader, and include the components of the abstract body listed below. Authors will be required to disclose all financial relationships through the online system, helping to ensure quality and unbiased presentations. However, the formal poster session is not designated for credit.
Share your research or best practices with your peers. Categories of submission include:
Hematologic Malignancies Gastrointestinal Cancers
Head and Neck Cancers
Central Nervous System Tumors, Neuroendocrine Tumors
Soft Tissue Sarcoma
Melanoma and other Cutaneous Malignancies
Targeted Therapies, Regional Therapies, Chemotherapies
Personalized and Precision Medicine
Biomarkers, Testing, Sequencing
Survivorship, Patient Care Management, Team-Based Care
Healthcare Reform, Value-Based Care, Clinical Pathways
The Program Chairs and Steering Committee will evaluate the scientific quality of the submitted abstracts based on the following criteria: novelty of the research, significance of the findings, and clarity. Incomplete abstracts will not be reviewed.
Notification of acceptance or regret will be delivered via e-mail to the presenters of each poster abstract by mid-September. Please note that an author is required to be present during the poster session.
If accepted for presentation, abstracts and posters will be available for viewing online on the 2017 Chemotherapy Foundation Symposium website during and after the conference. A formal poster viewing will be held during the conference in the Exhibit Hall, where breakfast and refreshment breaks will also be held. The presentation at the conference should reflect the submitted abstract; abstract title, authorship, and content of the presentation must match the submitted abstract.
All presenters must register to attend the 35th Annual Chemotherapy Foundation Symposium. Please visit www.gotoper.com to register.
Complete the abstract template provided on the 2017 Chemotherapy Foundation Symposium website.
Limit is 2500 characters (abstract body, including spaces and table).
Upload full abstract or poster where prompted.
Components of the abstract body – Limit: 2500 characters (1 table allowed)
Background/Significance — What was the problem and why was it important? What knowledge are you building on? What was the intent or goal of the study? What did you want to learn?
Materials and Methods — What was the trial design? What was the sample? What instruments were used? How were data collected and analyzed?
Results — What were the findings?
Conclusions — What do the findings mean?
TIP abstracts are accepted.
Encore abstracts are accepted.
Please submit any questions pertaining to abstract submissions to email@example.com using the subject line “CFS Abstract QUESTION.”
Author Consent and Waiver of Claims
Each Abstract Author agrees and certifies that he or she:
Waives any and all claims against Physicians’ Education Resource®, LLC, sponsor of the 35th Annual Chemotherapy Foundation Symposium, and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
Note: The hotel may sell out, and may to do so before the discounted cutoff date of October 16, 2017. Reservations should be made early!
Abstract submission deadline 2017-08-15
Physicians' Education Resource, LLC
Physicians' Education Resource, LLC